ArticleMedeniyet medical journal2026
Article in Medeniyet medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: CDH1 polymorphism has been suggested to be associated with susceptibility to gastric cancer (GC). However, relevant findings remain inconsistent across studies. This meta‑analysis was performed to evaluate the relationship between CDH1 -160C/A and -347G/GA polymorphisms and GC risk. Methods: Relevant studies were searched in PubMed, Web of Science, Google Scholar, Cochrane Library, Embase, CNKI, and Wanfang databases up to December 20, 2025. Pooled OR and 95% (95% CI) were calculated using fixed‑ or random‑effects models. Results: A total of 25 articles were included, involving 28 studies (4,836 cases and 6,187 controls) for the -160C/A polymorphism and 8 studies (1,201 cases and 1,611 controls) for the -347G/GA polymorphism. Overall, significant associations were identified between CDH1 polymorphisms and GC risk: -160C/A (recessive model: OR=1.28, 95% CI: 1.03-1.58; AA vs. CC: OR=1.28, 95% CI: 1.01-1.61); -347G/GA (G/GA vs. GG: OR=1.23, 95% CI: 1.04-1.44). In stratified analyses by histological type, the CDH1 -347G/GA polymorphism was associated with an elevated risk of diffuse‑type GC (G/GA vs. GG: OR=1.21, 95% CI: 1.01-1.62). Conclusions: This meta-analysis indicates that the two CDH1 promoter polymorphisms may contribute to GC susceptibility. Further large-scale and well-designed studies are needed to verify these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.